Leuprolide Mesylate (Camcevi) Coverage for Adolescent Gender Dysphoria
Customize your policy alerts
Sign up for all blue_shield_of_california policy alerts
Know when blue_shield_of_california releases new policies or updates existing guidance.
Monitor payer policy activity
Commercial medical benefit drug policy governing coverage and prior authorization requirements for leuprolide mesylate (Camcevi) administered for gender dysphoria in adolescents.
ICD-10 code F64.0 was added to the policy diagnosis code list.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.